RAC
vs
S
S&P/ASX 300
RAC
Over the past 12 months, RAC has significantly outperformed S&P/ASX 300, delivering a return of +92% compared to the S&P/ASX 300's +9% growth.
Stocks Performance
RAC vs S&P/ASX 300
Performance Gap
RAC vs S&P/ASX 300
Performance By Year
RAC vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Race Oncology Ltd
Glance View
Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The firm is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.
